/** blogpostTitle: "Stallion India Fluorochemicals: Q1 FY27 margin spike, and the real test ahead" blogpostSlug: "stallion-q1fy27" blogpostCoverImageUrl: null blogpostCoverImageDescription: "An ultra-realistic corporate finance scene showing a clean desk with a laptop displaying a simple financial dashboard: a bar chart for quarterly revenue rising from about 110 to 125 crore and a steeper bar chart for EBITDA rising from about 14 to 25 crore, alongside a line graph of improving EBITDA margin. In the background, a subtle industrial setting with gas storage tanks silhouettes suggesting multiple facilities. No logos or text labels, neutral lighting, professional financial aesthetic." blogpostShortTitle: "Stallion Q1 FY27 margins and expansion" */

Stallion India Fluorochemicals: Q1 FY27 margin spike, and the real test ahead

Stallion India Fluorochemicals Limited opened FY27 with a quarter that looked stronger on profitability than on topline. For Q1 FY27 (quarter ended 30 June 2026), the company reported total revenue of 124.68 crore, up 12.78% year on year. EBITDA rose sharply to 25.27 crore, up 75.85%, while PAT increased to 18.57 crore, up 79.15%.

The management narrative in the earnings call was consistent with what the investor presentation set up. This is a business trying to move from a gas handling and distribution-led model into a more integrated platform, anchored by three parallel growth levers: high-purity helium at Khalapur, a new debulking and blending hub at Mambattu in Andhra Pradesh, and a 10,000 MT R-32 manufacturing unit at Bhilwara, Rajasthan.

At the same time, management was careful about expectations. It described Q1 FY27 as a special quarter and explicitly said margins at this level may not repeat consistently. That caution matters because the quarter saw unusually large profitability expansion relative to revenue growth.

Q1 FY27: revenue grew, but margin expansion did the heavy lifting

On the call, the Managing Director attributed the EBITDA and PAT surge to a combination of better product mix and better planning. The company also referenced disruptions in imports and logistics linked to the Gulf crisis, which influenced pricing dynamics. When asked directly about inventory gains, management said the improvement was a mix and indicated roughly a 50:50 split between operational factors and inventory or stock-related benefit.

This is an important qualifier for investors. A quarter that benefits materially from inventory positioning can still reflect good execution, but it may not be a clean baseline for the next three quarters. Management did not attempt to sell the quarter as a new normal. Instead, it stated that profitability should improve over time, but the exact pace will depend on market conditions and the ramp-up of new projects.

Note: Values converted from INR lakhs to crore.

The integration roadmap: helium, Mambattu, and R-32 manufacturing

The investor presentation frames the company’s next phase as an integration roadmap, with an expected medium-term EBITDA margin improvement of about 3% to 4%. The building blocks behind that statement are now visible in the project list.

First is the Khalapur high-purity helium processing or handling plant. The presentation states installed capacity of 1,200 metric tonnes per annum. On the call, management said preparations were complete and commercial operations are expected to begin in the coming quarter. It also said helium revenue should start showing up from the next quarter after Q1 FY27.

Helium is positioned as a move into higher-value specialty gases with end-use exposure in semiconductors and electronics, healthcare applications like MRI, aerospace and defence, fiber optics and research. The presentation also highlights a long-term strategic sourcing partnership with Sharjah Oxygen Company L.L.C., enabling sourcing of liquid helium linked to RAS Gases and Oilfields, Qatar. Management spent meaningful time explaining supply security and described swap mechanisms for sourcing. It also stated that the helium outlook for the next two to three years includes a shortfall and higher pricing.

However, management also pushed back on simplistic ramp assumptions. Even though the plant capacity is large, it said the business will scale gradually. It guided that this year would see about five containers given it is a partial year, then 12 next year and 24 after that.

Second is the Mambattu facility. In the presentation, it is described as an HFO and HFC blending plus debulking plant, with planned capacity of 7,200 MT per annum, expected by end of Q3 FY26-27. It will handle HFC, HFO and blends, will include hydrocarbon handling, and is planned to also have helium and semiconductor gases capability similar to Khalapur.

In the call, the management explained that Mambattu’s timeline moved because the initial scope was expanded from a smaller configuration to a much larger 12-tank structure with more capabilities. It also cited local monsoon disruption in the region and said internal engineering bandwidth was prioritized to accelerate the Bhilwara R-32 project.

Third, and most material, is the 10,000 MT R-32 manufacturing facility at Bhilwara. The investor presentation states that environmental clearance was received from SEIAA Rajasthan on 28 December 2025, valid for 10 years, and that work has commenced on the greenfield plant. The project details disclosed include a by-product of hydrochloric acid (HCl 30%) and blended refrigerants capacity of 7,500 MT per annum in aggregate.

On timing, there is a difference between the presentation and the call. The presentation cites expected commissioning in October 2026 and mentions production projection from October 2026 to March 2027. On the call, management stated it is targeting completion by end of December 2026, and explained that funding came in later than originally planned due to a shift in fundraising route, which pushed the start of work.

This matters for near-term numbers. The presentation’s topline potential of 250 crore in FY26-27 implicitly assumed more months of production. In the call, management acknowledged that FY27 contribution would change and indicated that if the plant contributes in Q4, revenue could be closer to a one-quarter run contribution.

Still, for FY28, management maintained that the 500 to 600 crore annual revenue potential remains intact.

Guidance, capex thinking, and what to watch next

Management maintained guidance of 30% to 35% revenue CAGR over the next three years. It reiterated that as backward integration and higher value specialty gases rise, EBITDA margin could improve by about 3% to 4% over the medium term.

Another forward-looking theme was capital planning. Management said it would like to avoid further equity dilution, but also acknowledged that if the company wants to move faster on subsequent projects, including an HFO manufacturing plant, it may need to raise funds rather than rely only on internal accruals or push leverage too far. It did not announce a fundraising plan, but it clearly signaled that funding strategy could evolve with the pace of expansion.

HFO manufacturing was discussed both in the presentation and the call. The presentation mentions an MoU with the Government of Rajasthan for an HFO manufacturing plant at Bhilwara, with proposed investment of about 200 crore and construction to commence end-2027, and notes that land has been acquired. In the call, management discussed HFO as the next major step after R-32, provided an indicative capex range of 350 to 400 crore, and spoke about capacity planning, while emphasizing that any steps would respect IP protections of existing partners.

For investors, the next few quarters should be less about debating one quarter’s margin and more about tracking three execution milestones:

1. Whether helium revenue begins in the next quarter as guided and how quickly volumes scale.

2. Whether Mambattu reaches commissioning within the stated year-end window and what it does to logistics efficiency and mix.

3. Whether Bhilwara R-32 stays on track for end-December 2026 completion, and how much FY27 revenue it realistically contributes given that timing.

The Q1 FY27 margin spike was real, but management itself labeled it non-repeatable. The durable part of the story is the integration-led shift in business model. If execution holds, FY28 is where the company expects a step-change in scale, with management discussing a combined revenue trajectory that could exceed 1,100 crore with about 15% PAT margin in that scenario. Those are management statements rather than audited outcomes, and the path runs directly through project delivery and ramp-up discipline.